A recent report has shown that combined use of PARP inhibitors (niraparib, rucaparib, olaparib, BMN-673, talazoparib, or veliparib) and temozolomide inhibited proliferation and induced apoptosis of Ewing sarcoma cells [24, 37]. Here, PARP1 is linked to Ewing sarcoma.